Adherence, preference, and satisfaction of postmenopausal women taking denosumab or alendronate

Osteoporosis International

Volumn 22, Issue 6, 2011, Pages 1725-1735

  Kendler, D L ^a   McClung, M R ^b   Freemantle, N ^c   Lillestol, M ^d   Moffett, A H ^e   Borenstein, J ^f   Satram Hoang, S ^g   Yang, Y C ^g   Kaur, P ^g   Macarios, D ^g   Siddhanti, S ^g  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b OREGON OSTEOPOROSIS CENTER   (United States)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d Internal Medicine Associates   (United States)

^e OB GYN Associates of Mid Florida   (United States)

^f Cedars Sinai Health System   (United States)

^g AMGEN INC   (United States)

Author keywords

Adherence; Alendronate; Compliance; Denosumab; Persistence

Indexed keywords

ALENDRONIC ACID; AMINO TERMINAL TELOPEPTIDE; CARBOXY TERMINAL TELOPEPTIDE; DENOSUMAB;

AGED; ARTHRALGIA; BACKACHE; BONE DENSITY; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; DISEASE MARKER; DIVERTICULITIS; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; HYPOCALCEMIA; INFECTION; JAW OSTEONECROSIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUSCLE SPASM; NEOPLASM; OPEN STUDY; OSTEOARTHRITIS; PAIN; PATIENT COMPLIANCE; PATIENT SATISFACTION; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN INFECTION; SQUAMOUS CELL CARCINOMA; THORAX PAIN; TREATMENT OUTCOME; VERTEBRAL CANAL STENOSIS;

ADMINISTRATION, ORAL; AGED; ALENDRONATE; ANTIBODIES, MONOCLONAL; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BRITISH COLUMBIA; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MEDICATION ADHERENCE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PATIENT PREFERENCE; PATIENT SATISFACTION; TREATMENT OUTCOME;

EID: 79952673181     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-010-1378-z     Document Type: Conference Paper

References (41)

1. Johnell O, Kanis J (2005) Epidemiology of osteoporotic fractures. Osteoporos Int 16(Suppl 2):S3-S7 (Pubitemid 46232115)
2. Johnell O, Kanis JA (2004) An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporos Int 15:897-902 (Pubitemid 39506456)
3. Lips P, van Schoor NM (2005) Quality of life in patients with osteoporosis. Osteoporos Int 16:447-455
4. Shi N, Foley K, Lenhart G, Badamgarav E (2009) Direct healthcare costs of hip, vertebral, and non-hip, non-vertebral fractures. Bone 45:1084-1090
5. Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P (2008) Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev CD004523
6. Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P (2008) Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev CD003376
7. Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P (2008) Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev CD001155
8. Hiligsmann M, Rabenda V, Gathon HJ, Ethgen O, Reginster JY (2010) Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif Tissue Int 86:202-210
9. Siris ES, Harris ST, Rosen CJ, Barr CE, Arvesen JN, Abbott TA, Silverman S (2006) Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 81:1013-1022 (Pubitemid 44175011)
10. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C (2004) The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 15:1003-1008 (Pubitemid 40064656)
11. Huybrechts KF, Ishak KJ, Caro JJ (2006) Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone 38:922-928 (Pubitemid 44498580)
12. Tonino RP, Meunier PJ, Emkey R, Rodriguez-Portales JA, Menkes CJ, Wasnich RD, Bone HG, Santora AC, Wu M, Desai R, Ross PD (2000) Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 85:3109-3115
13. Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ (2007) Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 82:1493-1501 (Pubitemid 350211697)
14. Imaz I, Zegarra P, Gonzalez-Enriquez J, Rubio B, Alcazar R, Amate JM (2009) Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and metaanalysis. Osteoporos Int (in press)
15. Feldstein AC, Weycker D, Nichols GA, Oster G, Rosales G, Boardman DL, Perrin N (2009) Effectiveness of bisphosphonate therapy in a community setting. Bone 44:153-159
16. Kostenuik PJ (2005) Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength. Curr Opin Pharmacol 5:618-625 (Pubitemid 41614462)
17. Hofbauer LC, Schoppet M (2004) Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292:490-495 (Pubitemid 38988958)
18. Bekker PJ, Holloway DL, Rasmussen AS, Murphy R, Martin SW, Leese PT, Holmes GB, Dunstan CR, DePaoli AM (2004) A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19:1059-1066 (Pubitemid 41110556)
19. Brown JP, Prince RL, Deal C, Recker RR, Kiel DP, de Gregorio LH, Hadji P, Hofbauer LC, Alvaro-Gracia JM, Wang H, Austin M, Wagman RB, Newmark R, Libanati C, San Martin J, Bone HG (2009) Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial. J Bone Miner Res 24:153-161
20. Lewiecki EM, Miller PD, McClung MR, Cohen SB, Bolognese MA, Liu Y, Wang A, Siddhanti S, Fitzpatrick LA (2007) Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res 22:1832-1841 (Pubitemid 351229299)
21. Horne R, Weinman J, Hankins M (1999) The beliefs about medicines questionnaire: The development and evaluation of a new method for assessing the cognitive representation of medication. Psychol Health 14:1-24
22. Gold DT, Horne R, Hill C, Borenstein J, Varon S, Macarios D (2008) Development, reliability, and validity of a new Preference Satisfaction Questionnaire (PSQ). J Bone Miner Res 23:S210-S211
23. Gold DT, Safi W, Trinh H (2006) Patient preference and adherence: comparative US studies between two bisphosphonates, weekly risedronate and monthly ibandronate. Curr Med Res Opin 22:2383-2391 (Pubitemid 46055201)
24. Simon JA, Lewiecki EM, Smith ME, Petruschke RA, Wang L, Palmisano JJ (2002) Patient preference for once-weekly alendronate 70 mg versus once-daily alendronate 10 mg: a multicenter, randomized, open-label, crossover study. Clin Ther 24:1871-1886 (Pubitemid 35440956)
25. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain CD, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ, AMG 162 Bone Loss Study Group (2006) Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 354:821-831 (Pubitemid 43290920)
26. Miller PD, Bolognese MA, Lewiecki EM, McClung MR, Ding B, Austin M, Liu Y, San Martin J, AMG Bone Loss Study Group (2008) Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone 43:222-229
27. Kendler D, Kung AW, Fuleihan Gel H, Gonzalez Gonzalez JG, Gaines KA, Verbruggen N, Melton ME (2004) Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas 48:243-251 (Pubitemid 38781149)
28. Emkey R, Koltun W, Beusterien K, Seidman L, Kivitz A, Devas V, Masanauskaite D (2005) Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate Trial in Osteoporosis (BALTO). Curr Med Res Opin 21:1895-1903 (Pubitemid 41803098)
29. Hadji P, Minne H, Pfeifer M, Bourgeois P, Fardellone P, Licata A, Devas V, Masanauskaite D, Barrett-Connor E (2008) Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: a randomized, crossover study (BALTO II). Joint Bone Spine 75:303-310
30. Kastelan D, Lozo P, Stamenkovic D, Miskic B, Vlak T, Kolak Z, Milas Ahic J, Altabas V, Crncevic Orlic Z, Korsic M (2009) Preference for weekly and monthly bisphosphonates among patients with postmenopausal osteoporosis: results from the Croatian PROMO Study. Clin Rheumatol 28:321-326
31. Weiss M, Vered I, Foldes AJ, Cohen YC, Shamir-Elron Y, Ish-Shalom S (2005) Treatment preference and tolerability with alendronate once weekly over a 3-month period: an Israeli multi-center study. Aging Clin Exp Res 17:143-149 (Pubitemid 41558123)
32. McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J (2007) Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate. Bone 41:122-128 (Pubitemid 46901056)
33. Delmas PD, Vrijens B, Eastell R, Roux C, Pols HA, Ringe JD, Grauer A, Cahall D, Watts NB (2007) Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab 92:1296-1304 (Pubitemid 46556401)
34. Kendler DL, Ringe JD, Ste-Marie LG, Vrijens B, Taylor EB, Delmas PD (2009) Risedronate dosing before breakfast compared with dosing later in the day in women with postmenopausal osteoporosis. Osteoporos Int 20:1895-1902
35. Kendler DL, Bessette L, Hill CD, Gold DT, Horne R, Varon SF, Borenstein J, Wang H, Man HS, Wagman RB, Siddhanti S, Macarios D, Bone HG (2010) Preference and satisfaction with a 6-month subcutaneous injection versus a weekly tablet for treatment of low bone mass. Osteoporos Int 21:837-846
36. Brown C, Battista DR, Bruehlman R, Sereika SS, Thase ME, Dunbar-Jacob J (2005) Beliefs about antidepressant medications in primary care patients: relationship to self-reported adherence. Med Care 43:1203-1207 (Pubitemid 43012177)
37. Byer B, Myers LB (2000) Psychological correlates of adherence to medication in asthma. Psychol Health Med 5:389-393
38. Horne R, Buick D, Fisher M, Leake H, Cooper V, Weinman J (2004) Doubts about necessity and concerns about adverse effects: identifying the types of beliefs that are associated with nonadherence to HAART. Int J STD AIDS 15:38-44 (Pubitemid 38096128)
39. Horne R, Weinman J (1999) Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 47:555-567 (Pubitemid 30029305)
40. Horne R, Weinman J (2002) Self-regulation and self-management in asthma: exploring the role of illness perceptions and treatments beliefs in explaining non-adherence to preventer medication. Psychol Health 17:17-32
41. Freemantle N, Drummond M (1997) Should clinical trials with concurrent economic analyses be blinded? JAMA 277:63-64 (Pubitemid 27009043)